Development of RAD51 degraders for ovarian cancer treatment PARP inhibitor drugs have had a major impact on the clinical treatment of ovarian cancer in recent years, but they do not work in all patients. Many tumors have genetic mutations that make the tumor unable to repair damage to its DNA. PARP inhibitors exploit this fact […]
Read More
Nerves as novel actors in the tumor microenvironment: the role of exosomes in ovarian cancer tumor innervation Although advances in surgery and chemotherapy for ovarian cancer have improved survival, most women with ovarian cancer will experience recurrence of their disease. Unfortunately, recurrent ovarian cancers respond poorly to chemotherapy and are incurable, highlighting the need for […]
Read More
Tao Wu, PhDBaylor College of Medicine2020 Scientific Scholar Award Targeting Epigenetic Landscape Reprogramming to Combat Drug-resistance in Ovarian Cancer Despite major improvements in therapeutic approaches to ovarian cancer, the ability of tumors to develop resistance to anti-cancer drugs remains the major challenge in achieving longer-lasting remission. One of the ways drug resistance is thought to […]
Read More
T. Rinda Soong, MD, PhDUniversity of Pittsburgh2020 Scientific Scholar Award Early Serous Tubal Proliferations as Alternate Precursors of High-Grade Serous Carcinoma Identifying the origins of high grade serous ovarian cancer can help us understand how to prevent this disease or detect it at earlier, more treatable stages. Precancerous changes in fallopian tube tissue known as […]
Read More
Matjaz Barboric, PhDUniversity of Helsinki 2020 James A. Harting Pilot Study Award Targeting transcriptional kinases for novel ovarian cancer therapies Ovarian cancer is the deadliest gynecological cancer. Identifying druggable Achilles’ heels of ovarian cancer can lead to new treatments. In order to do this, Dr. Barboric will target critical enzymes called cyclin-dependent kinases (tCDKs) which […]
Read More
Keith Knutson, PhDMayo Clinic Jacksonville2020 Cookie Laughlin Pilot Study Award Combination Th17-inducing vaccination and immune checkpoint blockade for ovarian cancer treatment Several types of immunotherapies that use the person’s own immune system to attack foreign “cancer” cells while leaving normal cells alone are being tested in ovarian cancer. Using immunotherapy to activate an immune pathway […]
Read More
Ilana Chefetz, PhDUniversity of Minnesota – Twin Cities2020 Lynda’s Fund Pilot Study Award AMPK-alpha-like proteins in a high grade serous ovarian cancer Although epithelial ovarian cancer responds well to initial treatment, the cancer recurs in a significant number of women. Once ovarian cancer recurs it is generally lethal, with fewer than 10% of patients surviving […]
Read More
Joe Delaney, PhDMedical University of South Carolina2020 Pilot Study Award Slowing ovarian cancer evolution by LINE-1 inhibition High grade serous ovarian cancer is unique from other cancer types in that it has high levels of a type of DNA called LINE-1 elements. LINE-1 elements are known as selfish DNA because they can make copies of […]
Read More
Hua E Yu, PhDBeckman Research Institute of the City of Hope2020 Karla Mooers Pilot Study Award Targeting dePARylation activates anti-ovarian cancer immune responses The FDA has approved several types of PARP inhibitors for treating ovarian cancer. These drugs are especially effective at killing tumor cells that cannot repair damage that occurs to their DNA. One […]
Read More
Matthew Wakefield, PhDThe Walter & Eliza Hall Institute of Medical Research2020 Rosser Family Pilot Study Award Identifying all mutations in the PARP1 catalytic domain that impact PARP inhibitor action PARP inhibitors are a class of drugs that are becoming a major part of treatment for high grade ovarian cancer. These drugs kill cancer cells by […]
Read More